Compare Stocks: ATHX, CMND, EOCN, and GRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHX Athersys		$0.00	$0.01 ▼ $1.99	$833K	-0.9	1.77 million shs	4 shs
CMND Clearmind Medicine	$6.42 +2.1%	$9.77	$5.25 ▼ $3,840.00	$3.19M	0.93	37,162 shs	5,571 shs
EOCN Galmed Pharmaceuticals	$3.05 +1.3%	$4.35	$2.67 ▼ $12.32	$3.14M	0.66	8,204 shs	1,972 shs
GRI GRI Bio	$1.40	$1.90	$1.36 ▼ $64.12	$3.06M	-1.21	74,568 shs	28,502 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHX Athersys	0.00%	0.00%	0.00%	0.00%	0.00%
CMND Clearmind Medicine	+2.07%	-2.73%	-7.15%	-58.63%	-99.79%
EOCN Galmed Pharmaceuticals	+1.33%	-33.55%	-33.55%	-30.16%	-73.89%
GRI GRI Bio	0.00%	-16.67%	-23.08%	-6.67%	-97.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHX Athersys		$0.00	$0.01 ▼ $1.99	$833K	-0.9	1.77 million shs	4 shs
CMND Clearmind Medicine	$6.42 +2.1%	$9.77	$5.25 ▼ $3,840.00	$3.19M	0.93	37,162 shs	5,571 shs
EOCN Galmed Pharmaceuticals	$3.05 +1.3%	$4.35	$2.67 ▼ $12.32	$3.14M	0.66	8,204 shs	1,972 shs
GRI GRI Bio	$1.40	$1.90	$1.36 ▼ $64.12	$3.06M	-1.21	74,568 shs	28,502 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHX Athersys	0.00%	0.00%	0.00%	0.00%	0.00%
CMND Clearmind Medicine	+2.07%	-2.73%	-7.15%	-58.63%	-99.79%
EOCN Galmed Pharmaceuticals	+1.33%	-33.55%	-33.55%	-30.16%	-73.89%
GRI GRI Bio	0.00%	-16.67%	-23.08%	-6.67%	-97.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHX Athersys	0.00	N/A	N/A	N/A
CMND Clearmind Medicine	0.00	N/A	N/A	N/A
EOCN Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
GRI GRI Bio	2.33	Hold	$21.00	1,400.00% Upside

Current Analyst Ratings Breakdown

Latest ATHX, CMND, EOCN, and GRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	EOCN Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/15/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/13/2026	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/10/2026	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$10.00
7/17/2026	EOCN Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHX Athersys	$146K	0.00	N/A	N/A	($1.33) per share	0.00
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	$115.32 per share	N/A
EOCN Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHX Athersys	-$72.53M	-$2.03	N/A	N/A	N/A	N/A	N/A	-223.03%	N/A
CMND Clearmind Medicine	-$3.86M	-$324.40	N/A	N/A	N/A	N/A	-88.53%	-61.62%	N/A
EOCN Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	11/25/2026 (Estimated)
GRI GRI Bio	-$11.96M	-$38.37	N/A	N/A	N/A	N/A	-134.03%	-106.83%	11/13/2026 (Estimated)

Latest ATHX, CMND, EOCN, and GRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	GRI GRI Bio	-$0.84	N/A	N/A	N/A	N/A	N/A
9/10/2026	Q3 2026	CMND Clearmind Medicine	N/A	-$4.56	N/A	-$4.56	N/A	N/A
9/2/2026	Q2 2026	EOCN Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/14/2026	Q2 2026	GRI GRI Bio	-$1.19	-$0.91	+$0.28	-$0.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHX Athersys	N/A	N/A	N/A	N/A	N/A
CMND Clearmind Medicine	N/A	N/A	N/A	N/A	N/A
EOCN Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHX Athersys	N/A	0.06	0.06
CMND Clearmind Medicine	0.01	4.31	4.31
EOCN Galmed Pharmaceuticals	N/A	4.16	4.16
GRI GRI Bio	N/A	10.30	10.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHX Athersys	19.35%
CMND Clearmind Medicine	96.05%
EOCN Galmed Pharmaceuticals	76.14%
GRI GRI Bio	33.95%

Insider Ownership

Company	Insider Ownership
ATHX Athersys	0.03%
CMND Clearmind Medicine	N/A
EOCN Galmed Pharmaceuticals	19.80%
GRI GRI Bio	0.61%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHX Athersys	24	61.72 million	61.70 million	No Data
CMND Clearmind Medicine	4	507,000	N/A	Not Optionable
EOCN Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
GRI GRI Bio	5	2.19 million	2.17 million	Not Optionable

ATHX, CMND, EOCN, and GRI Headlines

Recent News About These Companies

GRI Bio (NASDAQ:GRI) Stock Price Down 2.6% - Here's Why

October 6, 2026 | americanbankingnews.com

Gri Bio, Inc. Highlights Immune Modulation and Phase 2A Development Insights in IPF At the 10Th IPF Summit

September 30, 2026 | marketscreener.comM

GRI Bio, Inc. met en avant la modulation immunitaire et les enseignements du développement en phase 2a dans la FPI lors du 10e IPF Summit

September 30, 2026 | zonebourse.comZ

GRI Bio to present Phase 2a IPF data at Boston summit

September 29, 2026 | streetinsider.com

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

September 28, 2026 | globenewswire.com

GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?

September 14, 2026 | zacks.com

UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy

September 14, 2026 | benzinga.com

GRI Bio Plans 52-Week Study Of GRI-0621 Following Phase 2a IPF Data

September 8, 2026 | rttnews.com

GRI Bio Reports Phase 2a Data Showing Repair Phenotype and FVC Improvement with GRI-0621 in Idiopathic Pulmonary Fibrosis

September 8, 2026 | quiverquant.comQ

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

September 8, 2026 | globenewswire.com

GRI Bio Featured in "Why Now" On-Demand Video Webcast

August 27, 2026 | globenewswire.com

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

August 24, 2026 | globenewswire.com

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

August 20, 2026 | nypost.comN

Banner Bank Releases New Corporate Responsibility Report

July 14, 2026 | gurufocus.com

GRI Bio Inc. (GRI) Holds Steady Near Key Support at $1.77 - Volatility Surface

July 14, 2026 | donanimhaber.comD

GRI Bio Inc.

June 26, 2026 | marketwatch.com

GRI Bio Secures FDA Orphan Drug Status for IPF

June 18, 2026 | tipranks.com

GRI Bio, Inc.: GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

June 18, 2026 | finanznachrichten.de

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

June 18, 2026 | globenewswire.com

GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

May 18, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX, CMND, EOCN, and GRI Company Descriptions

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

Clearmind Medicine NASDAQ:CMND

$6.42 +0.13 (+2.07%)

Closing price 10/15/2026 04:00 PM Eastern

Extended Trading

$6.70 +0.28 (+4.36%)

As of 07:41 AM Eastern

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Galmed Pharmaceuticals NASDAQ:EOCN

$3.05 +0.04 (+1.33%)

As of 10/15/2026 03:42 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GRI Bio NASDAQ:GRI

$1.40 0.00 (0.00%)

Closing price 10/15/2026 03:59 PM Eastern

Extended Trading

$1.43 +0.03 (+2.00%)

As of 07:06 AM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATHX, CMND, EOCN, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATHX, CMND, EOCN, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATHX, CMND, EOCN, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX, CMND, EOCN, and GRI Company Descriptions

Athersys NASDAQ:ATHX

Clearmind Medicine NASDAQ:CMND

Galmed Pharmaceuticals NASDAQ:EOCN

GRI Bio NASDAQ:GRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATHX, CMND, EOCN, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATHX, CMND, EOCN, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATHX, CMND, EOCN, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX, CMND, EOCN, and GRI Company Descriptions

Athersys NASDAQ:ATHX

Clearmind Medicine NASDAQ:CMND

Galmed Pharmaceuticals NASDAQ:EOCN

GRI Bio NASDAQ:GRI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools